[en] For years, bisphosphonates (BP) were known for their role in reducing the risk of skeletal related event in patients with bone metastases by accumulating and inhibiting the osteoclastic activity. Hence, since the emergence of germanium-68/gallium-68 generator for positron emission tomography (PET) imaging, developments in gallium-68 labelled BP for bone imaging have been looked into. Through the conjugation of a stable bifunctional chelator to a BP namely 2,2′-(7-(1-carboxy- 4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)- 1,4,7-triazonane-1,4-diyl)diacetic acid (NODAGA) and Pamidronic acid, this research aims to study the preparation, characterization, and in-vitro studies of [⁶⁸Ga]NODAGA-Pamidronic acid ([⁶⁸Ga]NODPAM) for PET bone imaging. NODAGA was conjugated to Pamidronic acid via NHS ester strategy. The conjugated precursor was characterized using tandem mass spectrometry (MS/MS) and purified using high performance liquid chromatography (HPLC). The conjugated NODAGA-Pamidronic acid was radiolabelled with gallium-68 in acetate buffer forming [⁶⁸Ga]NODPAM complex. The percentage radiochemical purity (%RCP) was assessed using radio-thin layer chromatography scanner (stationary phase: TLC-SG 60; mobile phase: acetonitrile:0.4M Phosphate (7:3)). The human plasma stability was studied 0.5 hourly for 2.5 hours. The bone binding assay of [⁶⁸Ga]NODPAM was performed using synthetic hydroxyapatite (HA) and was compared with [^99mTc]MDP. To visualize the retention of [⁶⁸Ga]NODPAM on bone, a preliminary PET image of fresh bone incubated in [⁶⁸Ga]NODPAM was performed.

[en] Ovarian cancer (OC) often presents at an advanced stage with frequent relapses despite optimal treatment; thus, accurate staging and restaging are required for improving treatment outcomes and prognostication. Conventionally, staging of OC is performed using contrast-enhanced computed tomography (CT). Nevertheless, recent advances in the field of hybrid imaging have made positron emission tomography/CT (PET/CT) and PET/magnetic resonance imaging (PET/MRI) as emerging potential noninvasive imaging tools for improved management of OC. Several studies have championed the role of PET/CT for the detection of recurrence and prognostication of OC. We provide a systematic review and meta-analysis of the latest publications regarding the role of molecular imaging in the management of OC. We retrieved 57 original research articles with one article having overlap in both diagnosis and staging; 10 articles (734 patients) regarding the role of PET/CT in diagnosis of OC; 12 articles (604 patients) regarding staging of OC; 22 studies (1429 patients) for detection of recurrence; and 13 articles for prognostication and assessment of treatment response. We calculated pooled sensitivity and specificity of PET/CT performance in various aspects of imaging of OC. We also discussed the emerging role of PET/MRI in the management of OC. We aim to give the readers and objective overview on the role of molecular imaging in the management of OC. (author)

[en] Highlights: • Inter-reader agreement was evaluated for contrast-enhanced PET/CT parameters using the liver as a reference organ. • Excellent inter-reader agreements were achieved for SUVmax, SULmean and SULmax. • A higher range of SULmax values (1.18 - 4.07) was observed in contrast-enhanced PET/CT scans. • Liver SULmax gave the best agreement and precision and should be clinically utilized for oncology treatment monitoring. - Abstract: PurposeTo evaluate the reliability of standardized uptake value (SUV) normalized to lean body mass for maximum (SULmax) and mean values (SULmean) as well as maximum SUV values (SUVmax) in contrast-enhanced 18F-FDG PET/CT by assessment of inter-reader agreement, using the liver as a reference organ.